Merck KGaA Awaiting EMA Response on NSCLC Erbitux Extension Based on Biomarker Expression Analysis
November 16, 2011
Merck KGaA Awaiting EMA Response on NSCLC Erbitux Extension Based on Biomarker Expression Analysis
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- After FDA Letter Seeking More Data, Lilly Won't Pursue CDx-Guided Erbitux in NSCLC in the US
May 2, 2012 / Pharmacogenomics Reporter - BMS, Amgen's Trials in Wild-Type KRAS Patients Could Clarify PGx Labeling for CRC Drugs
December 7, 2011 / Pharmacogenomics Reporter - FDA Official Says Vectibix/Erbitux Relabeling May Guide Sponsors on Agency's Criteria for Accepting Retrospective Data
October 7, 2009 / Pharmacogenomics Reporter - Study Finds KRAS Testing in Metastatic CRC Saves Money, but Questions Value of EGFR Inhibitors
November 28, 2012 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter